Clinical Trials Browser

Phase 2 × Hematologic Neoplasms × tafasitamab × Clear all

NCT06465433 2025-12-10

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Phase 2 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms